Royalty Sale Repeat: Vertex Adds $152M to Back CF Work
By Jennifer Boggs
Wednesday, November 20, 2013
Vertex Pharmaceuticals Inc. isn’t above using a good trick twice. Back in 2008, the Cambridge, Mass.-based firm picked up $160 million by selling royalty rights to two Glaxosmithkline plc-marketed drugs to help push through late-stage testing with then-game-changing hepatitis C virus (HCV) drug telaprevir. Fast forward five years, and Vertex again is opting for a royalty sale to pad its coffers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.